|
Kymriah (Tisagenlecleucel) is a cell-based gene treatment, and also known as CD19 chimeric antigen receptor (CAR) T-cell therapy. Kymriah has been authorized for the therapy of three blood cancers, which are Pediatric and Young Adult Relapsed or Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL), Adult r/r Diffuse Large B-cell Lymphoma (DLBCL) and Adult r/r Follicular Lymphoma (FL). Blood cancer is a disease that impacts on the blood cells. Some of the most prevalent types of blood cancer include lymphoma, leukemia and myeloma. Blood cancers account for roughly 10% of all cancer incidence in the US each year and 3% of all cancer-related deaths, according to estimates. Thus, it is urgent to research on the medicine that can treat the blood cancer, and Kymriah is a therapy that has been proved to be effective in treating this disease. However, some problems are still existed about the treatment of Kymriah, such as its serious side effects, Cytokine Release Syndrome (CRS) and Neurological Toxicities, and its high cost of treatment, which makes it difficult for patients from ordinary families to receive treatment in time. This article will introduce the mechanism, methods and side effects of Kymriah, as well as the clinical trials and results of Kymriah on three kinds of blood cancers, and put forward opinions and prospects for Kymriah.
|
